"Patients diagnosed with HR+/HER2- early breast cancer remain at risk of cancer recurrence, given that one-third of patients diagnosed with stage II and more than half of those diagnosed with stage III will unfortunately experience a return of their cancer," Dr. Shreeram Aradhye, chief medical officer of Novartis, said in a statement. "The compelling data from NATALEE [the clinical trial] highlight the potential of Kisqali to reduce the risk of cancer recurrence in this at-risk population, including node-negative patients, while maintaining a favorable safety profile. These potentially practice-changing results reinforce the unique and well-established profile of Kisqali as a proven treatment in HR+/HER2- metastatic breast cancer."
"breast" - Google News
June 02, 2023 at 08:32PM
https://ift.tt/G4tFkpE
FDA-approved drug found to reduce risk of breast cancer coming back - GMA
"breast" - Google News
https://ift.tt/FMwdeKQ
https://ift.tt/x68XlY1
Bagikan Berita Ini
0 Response to "FDA-approved drug found to reduce risk of breast cancer coming back - GMA"
Post a Comment